<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Comput Struct Biotechnol J</journal-id><journal-id journal-id-type="iso-abbrev">Comput Struct Biotechnol J</journal-id><journal-id journal-id-type="pmc-domain-id">2373</journal-id><journal-id journal-id-type="pmc-domain">csbj</journal-id><journal-title-group><journal-title>Computational and Structural Biotechnology Journal</journal-title></journal-title-group><issn pub-type="epub">2001-0370</issn><publisher><publisher-name>Research Network of Computational and Structural Biotechnology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9253833</article-id><article-id pub-id-type="pmcid-ver">PMC9253833.1</article-id><article-id pub-id-type="pmcaid">9253833</article-id><article-id pub-id-type="pmcaiid">9253833</article-id><article-id pub-id-type="pmid">35832625</article-id><article-id pub-id-type="doi">10.1016/j.csbj.2022.06.046</article-id><article-id pub-id-type="pii">S2001-0370(22)00260-4</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Identifies microtubule-binding protein <italic toggle="yes">CSPP1</italic> as a novel cancer biomarker associated with ferroptosis and tumor microenvironment</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wenwen</given-names></name></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jingjing</given-names></name></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yuqing</given-names></name></contrib><contrib contrib-type="author" id="au020"><name name-style="western"><surname>Xu</surname><given-names initials="Y">Yasi</given-names></name></contrib><contrib contrib-type="author" id="au025"><name name-style="western"><surname>Zhang</surname><given-names initials="S">Shirong</given-names></name><email>shirleyz4444@zju.edu.cn</email><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="af005">Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People&#8217;s Hospital, Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>shirleyz4444@zju.edu.cn</email></corresp></author-notes><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>24</day><month>6</month><year>2022</year></pub-date><volume>20</volume><issue-id pub-id-type="pmc-issue-id">395563</issue-id><fpage>3322</fpage><lpage>3335</lpage><history><date date-type="received"><day>24</day><month>4</month><year>2022</year></date><date date-type="rev-recd"><day>19</day><month>6</month><year>2022</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>06</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>12</day><month>07</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-08-25 13:25:27.197"><day>25</day><month>08</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder/><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" vol="21" journal-id="Comput Struct Biotechnol J" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC10651419"><article-title>Corrigendum to &#8220;Identifies microtubule-binding protein CSPP1 as a novel cancer biomarker associated with ferroptosis and tumor microenvironment&#8221; [Comput Struct Biotechnol J 20 (2022) 3322&#8211;3335]</article-title><volume>21</volume><date><day>1</day><month>11</month><year>2023</year></date><fpage>5394</fpage><lpage>5394</lpage><source>Computational and Structural Biotechnology Journal</source><pub-id pub-id-type="doi">10.1016/j.csbj.2023.10.048</pub-id><pub-id pub-id-type="pmcid">PMC10651419</pub-id><pub-id pub-id-type="pmid">38022700</pub-id></related-article><abstract abstract-type="graphical" id="ab005"><title>Graphical abstract</title><fig id="f0040" position="anchor" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></abstract><abstract abstract-type="author-highlights" id="ab010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#8226;</label><p id="p0005">Aberrant expression of CSPP1 serves as a diagnostic and prognostic biomarker in multiple cancers.</p></list-item><list-item id="o0015"><label>&#8226;</label><p id="p0015">Phosphorylation of CSPP1 at specific sites may regulate its activity.</p></list-item><list-item id="o0025"><label>&#8226;</label><p id="p0025">Functional enrichment indicates CSPP1 is potentially associated with ferroptosis and TME in LGG.</p></list-item><list-item id="o0030"><label>&#8226;</label><p id="p0030">CSPP1 dysregulates ferroptosis in LGG and other cancer types.</p></list-item><list-item id="o0035"><label>&#8226;</label><p id="p0035">CSPP1-associated tumors are infiltrated in different TMEs, improving ICB therapeutic efficacy in specific cancers.</p></list-item></list></p></abstract><abstract id="ab015"><p>Centrosome and spindle pole-associated protein (<italic toggle="yes">CSPP1</italic>) is a centrosome and microtubule-binding protein that plays a role in cell cycle-dependent cytoskeleton organization and cilia formation. Previous studies have suggested that <italic toggle="yes">CSPP1</italic> plays a role in tumorigenesis; however, no pan-cancer analysis has been performed. This study systematically investigates the expression of <italic toggle="yes">CSPP1</italic> and its potential clinical outcomes associated with diagnosis, prognosis, and therapy. <italic toggle="yes">CSPP1</italic> is widely present in tissues and cells and its aberrant expression serves as a diagnostic biomarker for cancer. <italic toggle="yes">CSPP1</italic> dysregulation is driven by multi-dimensional mechanisms involving genetic alterations, DNA methylation, and miRNAs. Phosphorylation of CSPP1 at specific sites may play a role in tumorigenesis. In addition, <italic toggle="yes">CSPP1</italic> correlates with clinical features and outcomes in multiple cancers. Take brain low-grade gliomas (LGG) with a poor prognosis as an example, functional enrichment analysis implies that <italic toggle="yes">CSPP1</italic> may play a role in ferroptosis and tumor microenvironment (TME), including regulating epithelial-mesenchymal transition, stromal response, and immune response. Further analysis confirms that <italic toggle="yes">CSPP1</italic> dysregulates ferroptosis in LGG and other cancers, making it possible for ferroptosis-based drugs to be used in the treatment of these cancers. Importantly, <italic toggle="yes">CSPP1</italic>-associated tumors are infiltrated in different TMEs, rendering immune checkpoint blockade therapy beneficial for these cancer patients. Our study is the first to demonstrate that <italic toggle="yes">CSPP1</italic> is a potential diagnostic and prognostic biomarker associated with ferroptosis and TME, providing a new target for drug therapy and immunotherapy in specific cancers.</p></abstract><kwd-group id="kg005"><title>Abbreviations</title><kwd>TME, tumor microenvironment</kwd><kwd>CAF, cancer-associated fibroblasts</kwd><kwd>EMT, epithelial-mesenchymal transition</kwd><kwd><italic toggle="yes">CSPP1</italic>, centrosome and spindle pole-associated protein</kwd><kwd>DLBC, diffuse large B-cell lymphoma</kwd><kwd>TCGA, The Cancer Genome Atlas</kwd><kwd>GTEx, Genotype-Tissue Expression</kwd><kwd>CPTAC, Clinical Proteomic Tumor Analysis Consortium</kwd><kwd>ROC, receiver operating characteristics</kwd><kwd>CNA, copy number alteration</kwd><kwd>KM, Kaplan-Meier</kwd><kwd>OS, overall survival</kwd><kwd>DSS, disease-specific survival</kwd><kwd>PFS, progression-free survival</kwd><kwd>ENCORI, Encyclopedia of RNA Interactomes</kwd><kwd>TISIDB, Tumor-Immune System Interactions DataBase</kwd><kwd>LGG, low-grade gliomas</kwd><kwd>PFI, progression-free interval</kwd><kwd>C-index, concordance index</kwd><kwd>DEGs, differentially expressed genes</kwd><kwd>GO, Gene Ontology</kwd><kwd>CC, cellular component</kwd><kwd>MF, molecular functions</kwd><kwd>BP, biological pathways</kwd><kwd>GSEA, Gene Set Enrichment Analysis</kwd><kwd>KEGG, Kyoto Encyclopedia of Genes and Genomes</kwd><kwd>GSVA, gene set variation analysis</kwd><kwd>TIMER, Tumor Immune Estimation Resource</kwd><kwd>MHC, major histocompatibility complex</kwd><kwd>TMB, tumor mutation burden</kwd><kwd>MSI, microsatellite instability</kwd><kwd>TIDE, Tumor Immune Dysfunction and Exclusion</kwd><kwd>CTL, cytotoxic T lymphocyte</kwd><kwd>ICB, immune checkpoint blockade</kwd><kwd>TGCT, testicular germ cell tumors, STAD, stomach adenocarcinoma</kwd><kwd>BRCA, breast invasive carcinoma</kwd><kwd>CHOL, cholangiocarcinoma</kwd><kwd>COAD, colon adenocarcinoma</kwd><kwd>ESCA, esophageal carcinoma</kwd><kwd>GBM, glioblastoma multiforme</kwd><kwd>HNSC, head and neck squamous cell carcinoma</kwd><kwd>LAML, acute myeloid leukemia</kwd><kwd>LIHC, liver hepatocellular carcinoma</kwd><kwd>PAAD, pancreatic adenocarcinoma</kwd><kwd>READ, rectum adenocarcinoma</kwd><kwd>THYM, thymoma</kwd><kwd>ACC, adrenocortical carcinoma</kwd><kwd>CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma</kwd><kwd>KICH, kidney chromophobe</kwd><kwd>KIRC, renal clear cell carcinoma</kwd><kwd>LUAD, lung adenocarcinoma</kwd><kwd>LUSC, lung squamous cell carcinoma</kwd><kwd>OV, ovarian serous cystadenocarcinoma</kwd><kwd>PRAD, prostate cancer</kwd><kwd>SKCM, skin cutaneous melanoma</kwd><kwd>THCA, thyroid cancer</kwd><kwd>UCEC, endometrial cancer uterine corpus endometrial carcinoma</kwd><kwd>UCS, uterine carcinosarcoma</kwd><kwd>FAG, ferroptosis-associated gene</kwd><kwd>FDG, ferroptosis-driver gene</kwd><kwd>FSG, ferroptosis-suppressor gene</kwd></kwd-group><kwd-group id="kg010"><title>Keywords</title><kwd><italic toggle="yes">CSPP1</italic></kwd><kwd>Biomarker</kwd><kwd>Ferroptosis</kwd><kwd>Tumor microenvironment</kwd><kwd>Pan-cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0040">Cancer is a leading cause of global health problems <xref rid="b0005" ref-type="bibr">[1]</xref>. Although cancer treatment methods have recently improved, clinical outcomes remain unsatisfactory due to side effects and drug resistance issues. Therefore, it is urgent to identify new sensitive biomarkers for the diagnosis and treatment of these cancer patients.</p><p id="p0045">Ferroptosis is a novel iron-dependent programmed cell death, that differs from typical cell death processes, mediated by lethal accumulation of lipid peroxides <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>. It involves a series of metabolic pathways and lipid peroxidation signaling pathways and is characterized by increased lipid peroxidation and reactive oxygen species, smaller mitochondria, and higher mitochondrial membrane density, but the change in nuclear morphology is not obvious <xref rid="b0020" ref-type="bibr">[4]</xref>. Ferroptosis is essentially an antitumor mechanism that suppresses tumor growth and kills these cells. Cancer cell ferroptosis not only promotes the antitumor response of immune cells but also affects the ferroptosis of immune cells themselves. Therefore, ferroptosis plays an important role in tumor occurrence, progression, and prognosis <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>.</p><p id="p0050">Tumor microenvironment (TME) is the surrounding microenvironment for tumor cells, mainly including peripheral blood vessels, stromal cells (cancer-associated fibroblasts (CAFs), endothelial cells, etc.), immune cells, and non-cellular components (cytokines, growth factors, hormones, and the extracellular matrix) <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>. Stromal components typically form a microenvironment conducive to tumor cell growth, including influencing metabolic pathways, inhibiting ferroptosis, inducing epithelial-mesenchymal transition (EMT), and regulating immune cell infiltration. Meanwhile, in the early stage, immune cells are recruited and activated by tumor cells to form an antitumor immune microenvironment and delay tumor development. With the continuous activation by tumor antigens, the relevant effector cells enter the depletion or remodeling stage, resulting in an immunosuppressive microenvironment. Different microenvironmental components interact and regulate each other, and are closely related to tumor progression and prognosis. Therefore, novel targets and biomarkers can be identified by identifying genes that influence ferroptosis and TME, leading to the selection of effective drugs and immunotherapy strategies to improve the prognosis of cancer patients.</p><p id="p0055">Centrosome and spindle pole-associated protein (<italic toggle="yes">CSPP1</italic>), encoded by chromosome 8q13.2, is initially identified as a highly expressed proto-oncogene in diffuse large B-cell lymphoma (DLBC) <xref rid="b0055" ref-type="bibr">[11]</xref>. It localizes to the interphase centrosome and mitotic spindle, migrates to the central spindle at the end of mitosis, and concentrates at the midbody during telophase and cytokinesis, thus functioning throughout cell cycle progression. Overexpression or suppression of <italic toggle="yes">CSPP1</italic> causes cell-cycle defects <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>. Interestingly, CSPP1 is not only localized to the centrosome and spindle in cycling cells but also interacts with Nephrocystin 8 to extend to the cilia axoneme in postmitotic resting cells, thus playing an important role in ciliogenesis. E3 ubiquitin-protein ligase UBR5-mediated ubiquitylation of CSPP1 is an underlying requirement for cilia localization. Meanwhile, interacting with the centrosomal protein of 104&#160;kDa (<italic toggle="yes">CEP104</italic>), CSPP1 regulates axoneme length and cilia formation in the Hedgehog signaling pathway <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>. Mutation or loss of function in <italic toggle="yes">CSPP1</italic> causes primary cilia abnormalities and ciliopathy, including Joubert syndrome and Meckel-Gruber syndrome <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>. Beyond cell cycle control and ciliogenesis, CSPP1 displays microtubule-independent but desmoplakin-dependent desmosome localization in apical-basal polarized epithelial cells and it is necessary for normal spheroid formation <xref rid="b0115" ref-type="bibr">[23]</xref>. More importantly, <italic toggle="yes">CSPP1</italic> has also been identified as a candidate oncogene in luminal breast cancer; meanwhile, nuclear <italic toggle="yes">CSPP1</italic> expression can define subtypes and clinical subgroups of basal-like breast carcinoma <xref rid="b0120" ref-type="bibr">[24]</xref>. In addition to DLBC, <italic toggle="yes">CSPP1</italic> is also identified as a putative hallmark gene associated with the malignancy of oral squamous cell carcinoma <xref rid="b0125" ref-type="bibr">[25]</xref>. However, no comprehensive analyses of the expression, function, and clinical significance of <italic toggle="yes">CSPP1</italic> as well as its correlation with ferroptosis and TME components have been performed.</p><p id="p0060">In this study, we systematically analyzed <italic toggle="yes">CSPP1</italic> expression and found that its aberrant expression is driven by genetic alterations, DNA methylation, and miRNAs. Phosphorylation of CSPP1 protein may regulate its activity, especially at Ser424. In addition, <italic toggle="yes">CSPP1</italic> strongly correlated with ferroptosis and TME components, potentially serving as a diagnostic and prognostic biomarker. Patients with <italic toggle="yes">CSPP1</italic>-associated tumors may benefit from ferroptosis-based drug therapy and immunotherapy by modulating ferroptosis and TME in several types of cancer.</p></sec><sec id="s0010"><label>2</label><title>Material and methods</title><sec id="s0015"><label>2.1</label><title>Data collection</title><p id="p0065">Transcriptomic data containing mRNA, miRNA, and associated clinical information were retrieved from The Cancer Genome Atlas (TCGA, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/repository" id="ir005">https://portal.gdc.cancer.gov/repository</ext-link>) and UCSC XENA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://xenabrowser.net" id="ir010">https://xenabrowser.net</ext-link>) databases <xref rid="b0130" ref-type="bibr">[26]</xref>. mRNA sequencing data in level 3 HTSeq-FPKM format was converted into TPM format, and miRNA sequencing data in level 3 BCGSC format was converted into RPM format; all data were downloaded from TCGA. UCSC XENA database contained both TCGA and Genotype-Tissue Expression (GTEx) data, which were processed by the Toil process into TPM format <xref rid="b0135" ref-type="bibr">[27]</xref>. The Oncomine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.oncomine.org/resource/login.html" id="ir015">https://www.oncomine.org/resource/login.html</ext-link>) image for <italic toggle="yes">CSPP1</italic> expression was downloaded (threshold: <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001; fold change &gt;2; gene rank: top 10%). R software (Version 3.6.3, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cran.r-project.org/bin/windows/base/old/3.6.3/" id="ir020">https://cran.r-project.org/bin/windows/base/old/3.6.3/</ext-link>) and ggplot2 R package (Version 3.3.3, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggplot2/index.html" id="ir025">https://cran.r-project.org/web/packages/ggplot2/index.html</ext-link>) were used to statistical analyses and visualization, respectively.</p></sec><sec id="s0020"><label>2.2</label><title>Differential expression analysis</title><p id="p0070">RNA sequencing data in TPM or FPKM format for <italic toggle="yes">CSPP1</italic> expression in tissues and single cells were recorded from the Human Protein Atlas portal (HPA, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.proteinatlas.org/" id="ir030">https://www.proteinatlas.org/</ext-link>) and visualized by radar plots. To compare <italic toggle="yes">CSPP1</italic> and miRNA expression in normal and tumor tissues, an unpaired Wilcoxon rank-sum test was performed using TCGA and GTEx datasets. Histograms of CSPP1 protein expression and site phosphorylation levels in normal and primary tumor tissues were downloaded from the UALCAN portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ualcan.path.uab.edu/analysis-prot.html" id="ir035">https://ualcan.path.uab.edu/analysis-prot.html</ext-link>) using Clinical Proteomic Tumor Analysis Consortium (CPTAC) data <xref rid="b0140" ref-type="bibr">[28]</xref>.</p></sec><sec id="s0025"><label>2.3</label><title>Diagnostic analysis</title><p id="p0075">The diagnostic value of <italic toggle="yes">CSPP1</italic> was estimated using RNA-sequencing data from TCGA and visualized by a receiver operating characteristics (ROC) curve using the pROC R package (Version 1.17.0.1, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/pROC/index.html" id="ir040">https://cran.r-project.org/web/packages/pROC/index.html</ext-link>).</p></sec><sec id="s0030"><label>2.4</label><title>Genetic alterations and DNA methylation analysis</title><p id="p0080">Histograms of <italic toggle="yes">CSPP1</italic> mutation and copy number alteration (CNA) frequency in pan-cancer (TCGA, PanCancer Atlas) were downloaded from the cBioPortal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cbioportal.org/" id="ir045">https://www.cbioportal.org/</ext-link>). Histograms of <italic toggle="yes">CSPP1</italic> promoter methylation in normal and primary tumor tissues were downloaded from the UALCAN portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ualcan.path.uab.edu/index.html" id="ir050">https://ualcan.path.uab.edu/index.html</ext-link>) <xref rid="b0145" ref-type="bibr">[29]</xref>. Correlations between <italic toggle="yes">CSPP1</italic>, CNAs, and DNA methylation (TCGA, Firehose) were recorded from cBioPortal and visualized by heatmaps. Dot size together with transition color represented the degree of correlation. The larger the dot, the stronger the correlation. Red and blue dots represented positive and negative correlations, respectively. Kaplan-Meier (KM) plots of these alterations on survival probability, including that of overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS), were downloaded from cBioPortal.</p></sec><sec id="s0035"><label>2.5</label><title>Correlations between CSPP1 and associated miRNAs</title><p id="p0085">Spearman correlations between <italic toggle="yes">CSPP1</italic> and associated miRNAs were recorded from the Encyclopedia of RNA Interactomes portal (ENCORI, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://rna.sysu.edu.cn/encori/index.php" id="ir055">https://rna.sysu.edu.cn/encori/index.php</ext-link>) (parameter setting: assembly, hg38; miRNA: all; CLIP-Data&#160;&#8805;&#160;3; pan-Cancer&#160;&#8805;&#160;1; programNum&#160;&#8805;&#160;2; target, <italic toggle="yes">CSPP1</italic>) and visualized by a heatmap <xref rid="b0150" ref-type="bibr">[30]</xref>.</p></sec><sec id="s0040"><label>2.6</label><title>Correlations between CSPP1 and clinical features</title><p id="p0090">Correlations between <italic toggle="yes">CSPP1</italic>, pathologic stage, and histologic grade from TCGA database were analyzed using the Kruskal-Wallis test and visualized by violin plots. Correlations between <italic toggle="yes">CSPP1</italic> and molecular subtype were also analyzed with the Kruskal-Wallis test and the violin plots were downloaded from Tumor-Immune System Interactions DataBase (TISIDB, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cis.hku.hk/TISIDB/index.php" id="ir060">https://cis.hku.hk/TISIDB/index.php</ext-link>) <xref rid="b0155" ref-type="bibr">[31]</xref>.</p><p id="p0095">Correlations between <italic toggle="yes">CSPP1</italic> and clinical features in brain low-grade gliomas (LGG) were analyzed using the Chi-squared test or Fisher&#8217;s exact test and visualized by a baseline datasheet.</p></sec><sec id="s0045"><label>2.7</label><title>Prognostic analysis of CSPP1 and associated miRNAs, model construction, and evaluation</title><p id="p0100">Survival differences analyses of <italic toggle="yes">CSPP1</italic> and associated <italic toggle="yes">miRNAs</italic>, including OS, DSS, and progression-free interval (PFI), were visualized by forest plots based on KM analyses. The Survivin R package (Version 3.2-10, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/survivalAnalysis/index.html" id="ir065">https://cran.r-project.org/web/packages/survivalAnalysis/index.html</ext-link>) was used for statistical analysis, and the survminer R package (Version 0.4.9, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/survminer/index.html" id="ir070">https://cran.r-project.org/web/packages/survminer/index.html</ext-link>) was used for visualization.</p><p id="p0105">Univariate and multivariate Cox regression analyses were visualized by forest plots. Based on multivariate Cox regression, risk score plots were constructed using the ggrisk R package (Version 1.3, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggrisk/index.html" id="ir075">https://cran.r-project.org/web/packages/ggrisk/index.html</ext-link>). Nomograms were also designed using the rms R package (Version 6.2-0, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/rms/index.html" id="ir080">https://cran.r-project.org/web/packages/rms/index.html</ext-link>) and survival R package <xref rid="b0130" ref-type="bibr">[26]</xref>. Calibration curves and the concordance index (C-index) were evaluated by comparing predicted probabilities with observed events.</p></sec><sec id="s0050"><label>2.8</label><title>Functional enrichment analysis in LGG</title><p id="p0110"><italic toggle="yes">CSPP1</italic>-associated differentially expressed genes (DEGs) in LGG were identified using the limma R package (Version 3.40.2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/limma.html" id="ir085">https://bioconductor.org/packages/release/bioc/html/limma.html</ext-link>) and visualized by a volcano plot <xref rid="b0160" ref-type="bibr">[32]</xref>. Spearman correlations between <italic toggle="yes">CSPP1</italic> and the top 20 DEGs were assessed and visualized by a heatmap.</p><p id="p0115">DEGs were used for Gene Ontology (GO) enrichment analyses, including cellular components (CCs), molecular functions (MFs), and biological pathways (BPs). Gene Set Enrichment Analysis (GSEA) was also conducted to detect phenotypes and signaling pathways. Hallmark v7.2, GO c5 v7.2 (BPs, CCs, MFs), and Kyoto Encyclopedia of Genes and Genomes (KEGG) c2 v7.2 gene sets were used. Statistical analysis and graphical charting were performed using the clusterProfiler R package (Version 3.14.3, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html" id="ir090">https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html</ext-link>) <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>.</p></sec><sec id="s0055"><label>2.9</label><title>Gene mutation and ferroptosis correlation analysis</title><p id="p0120">Somatic mutations in LGG from TCGA database were analyzed using the maftools R package (Version 3.14, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/maftools.html" id="ir095">https://bioconductor.org/packages/release/bioc/html/maftools.html</ext-link>) and visualized by an oncoplot <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>. Ferroptosis-associated score was calculated with the gene set extracted from KEGG with the ssGSEA algorithm in the gene set variation analysis (GSVA) package (Version 1.34.0, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bioconductor.riken.jp/packages/3.0/bioc/html/GSVA.html" id="ir100">https://bioconductor.riken.jp/packages/3.0/bioc/html/GSVA.html</ext-link>), and the difference between the driver score minus suppressor score was defined as the ferroptosis score to represent the ferroptosis status of samples <xref rid="b0180" ref-type="bibr">[36]</xref>. Spearman correlations between <italic toggle="yes">CSPP1</italic> and ferroptosis-related genes and ferroptosis scores were analyzed and visualized by heatmaps.</p></sec><sec id="s0060"><label>2.10</label><title>TME analysis and immune checkpoint blockade therapy prediction</title><p id="p0125">TCGA datasets were used to analyze the Spearman correlations between <italic toggle="yes">CSPP1</italic> and immune cells using the ssGSEA algorithm in the GSVA package. They were also used to estimate the stromal score, immune score, and ESTIMATE score using the ESTIMATE package (Version 1.0.13, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bioinformatics.mdanderson.org/estimate/index.html" id="ir105">https://bioinformatics.mdanderson.org/estimate/index.html</ext-link>) <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>. Purity-adjusted Spearman correlations between <italic toggle="yes">CSPP1</italic> and CAFs, endothelial cells, and immune checkpoints were recorded from the Tumor Immune Estimation Resource 2 portal (TIMER2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://timer.cistrome.org" id="ir110">https://timer.cistrome.org</ext-link>) with XCELL or TIMER algorithm <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>. The Spearman correlations between <italic toggle="yes">CSPP1</italic> and major histocompatibility complex (MHC) molecules, immune stimulator genes, immune inhibitor genes, tumor mutation burden (TMB) score, and microsatellite instability (MSI) score from the TCGA database were analyzed <xref rid="b0205" ref-type="bibr">[41]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>. All corresponding correlations were visualized by heatmaps.</p><p id="p0130">Tumor Immune Dysfunction and Exclusion (TIDE, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tide.dfci.harvard.edu/" id="ir115">https://tide.dfci.harvard.edu/</ext-link>) is a comprehensive score for tumor immune dysfunction and immune escape, including tumor-infiltrating cytotoxic T lymphocyte (CTL) dysfunction and rejection by immune checkpoints. RNA-sequencing raw count data and corresponding clinical information from TCGA database were estimated using the TIDE algorithm to predict the potential immune checkpoint blockade (ICB) response. A low score indicated good efficacy <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0220" ref-type="bibr">[44]</xref>.</p></sec></sec><sec id="s0065"><label>3</label><title>Results</title><sec id="s0070"><label>3.1</label><title>Aberrant expression of CSPP1 serves as a diagnostic biomarker among cancers</title><p id="p0135"><italic toggle="yes">CSPP1</italic> was widely present in all the tested tissues and cells. It was highly expressed in skeletal muscle, testis, and fallopian tube, as well as in respiratory ciliated cells, endometrial ciliated cells, and early spermatids; meanwhile, high expression was observed in testicular germ cell tumors (TGCT), stomach adenocarcinoma (STAD), and breast invasive carcinoma (BRCA) (<xref rid="f0005" ref-type="fig">Fig. 1</xref>A&#8211;C).<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Aberrant expression of <italic toggle="yes">CSPP1</italic> serves as a diagnostic biomarker among cancers. (A) Radar Plot of <italic toggle="yes">CSPP1</italic> expression in normal tissues basedon GTEx datasets from HPA portal. (B) Radar Plot of <italic toggle="yes">CSPP1</italic> expression in single cells based on single-cell types dataset from HPA portal. (C) Radar Plot of <italic toggle="yes">CSPP1</italic> expression in tumor tissues based on TCGA dataset from HPA portal. (D, E) Histogram of <italic toggle="yes">CSPP1</italic> expression in 33 types of unpaired normal and tumor tissues from TCGA and TCGA plus GTEx database using Wilcoxon rank-sum test. ns: <italic toggle="yes">p</italic>&#160;&#8805;&#160;0.05, * <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01, *** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001. (F) Heatmap of <italic toggle="yes">CSPP1</italic> expression from Oncomine portal. (G, H) ROC analyses of differential <italic toggle="yes">CSPP1</italic> expression in 27 types of upregulated (G) and downregulated (H) cancer from TCGA and GTEx databases. AUC&#160;&gt;&#160;0.9 was considered a high diagnostic value, 0.9&#160;&#8805;&#160;AUC&#160;&gt;&#160;0.7 was median, and 0.7&#160;&#8805;&#160;AUC&#160;&gt;&#160;0.5 was low.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0140">To compare <italic toggle="yes">CSPP1</italic> expression in human adjacent normal versus 33 types of tumor tissues, TCGA datasets were used. <italic toggle="yes">CSPP1</italic> was significantly upregulated in ten cancer types and downregulated in five from TCGA (<xref rid="f0005" ref-type="fig">Fig. 1</xref>D). In order to expand the sample size, we also introduced normal samples from the GTEx database. <italic toggle="yes">CSPP1</italic> expression was increased in BRCA, cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), DLBC, esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), acute myeloid leukemia (LAML), LGG, liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), STAD, and thymoma (THYM). In contrast, its expression was decreased in adrenocortical carcinoma (ACC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney chromophobe (KICH), renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), prostate cancer (PRAD), skin cutaneous melanoma (SKCM), TGCT, thyroid cancer (THCA), endometrial cancer uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS) (<xref rid="f0005" ref-type="fig">Fig. 1</xref>E). Thereafter, we used the Oncomine datasets to validate <italic toggle="yes">CSPP1</italic> expression patterns. Significantly elevated <italic toggle="yes">CSPP1</italic> expression was observed in most cancer types; however, its expression was reduced in bladder cancer and kidney cancer (<xref rid="f0005" ref-type="fig">Fig. 1</xref>F). Combined with these databases, 27 cancers with differential <italic toggle="yes">CSPP1</italic> expression from GTEx plus TCGA database were used in subsequent analyses.</p><p id="p0145">ROC analyses with TCGA or TCGA plus GTEx datasets indicated that the diagnostic values of <italic toggle="yes">CSPP1</italic> were median or high in CHOL, DLBC, ESCA, HNSC, LAML, PAAD, STAD, THYM, ACC, CESC, KICH, LUAD, LUSC, OV, TGCT, THCA, and UCS (<xref rid="f0005" ref-type="fig">Fig. 1</xref>G, H). Our results indicated that aberrant <italic toggle="yes">CSPP1</italic> expression serves as a diagnostic biomarker among cancers.</p></sec><sec id="s0075"><label>3.2</label><title>Multi-dimensional mechanisms involving genetic alterations, DNA methylation, and miRNAs underly CSPP1 dysregulation</title><p id="p0150">To determine the cause underlying <italic toggle="yes">CSPP1</italic> dysregulation, we comprehensively analyzed the factors related to the expression of <italic toggle="yes">CSPP1</italic>, including genetic variation, DNA methylation, and associated miRNAs. We first used cBioPortal to study the genetic variation and found that among these 26 cancer types (COAD and READ were combined into COADREAD in the Portal), 21 contained mutations and 21 had CNAs (<xref rid="f0010" ref-type="fig">Fig. 2</xref>A). Except for UCEC (&gt;5%), <italic toggle="yes">CSPP1</italic> mutation frequencies were relatively low in most cancers (&lt;5%). These mutations caused poor PFS in SKCM and good PFS in UCEC (<xref rid="s0130" ref-type="sec">Fig. S1</xref>A). CNA is the genetic variation most closely associated with <italic toggle="yes">CSPP1</italic> expression <xref rid="b0225" ref-type="bibr">[45]</xref>. It occurred more frequently in UCS, PRAD, LIHC, BRCA, and OV (&gt;5%). <italic toggle="yes">CSPP1</italic> positively correlated with CNAs (<xref rid="f0010" ref-type="fig">Fig. 2</xref>B; <xref rid="s0130" ref-type="sec">Table S1</xref>) and had worse DSS and PFS in COADREAD, as well as worse OS, DSS, and PFS in PAAD, PRAD, STAD, and UCEC (<xref rid="s0130" ref-type="sec">Fig. S1</xref>B).<fig id="f0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Multi-dimensional mechanisms involving genetic alterations, DNA methylation, and miRNAs underly <italic toggle="yes">CSPP1</italic> dysregulation. (A) Histogram of genetic alteration frequency of <italic toggle="yes">CSPP1</italic> from cBioPortal portal. (B) A heatmap of correlations between <italic toggle="yes">CSPP1</italic> and CNAs. Dot size together with transition color represented the degree of correlation. The larger the dot, the stronger the correlation. Red and blue represented positive and negative correlations, respectively. * <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01. (C) Histograms of <italic toggle="yes">CSPP1</italic> promoter methylation in normal and primary tumors with significant differences from UALCAN portal. 0.7&#160;&#8805;&#160;Beta value&#160;&gt;&#160;0.5 was considered hyper-methylation, 0.3&#160;&#8805;&#160;Beta value&#160;&gt;&#160;0.25 was hypo-methylation. (D) A heatmap of correlations between <italic toggle="yes">CSPP1</italic> and DNA methylation from cBioPortal portal. (E) A heatmap of correlation between <italic toggle="yes">CSPP1</italic> and predicted miRNAs from ENCORI portal. Red and blue words indicated upregulated and downregulated cancers, respectively. (F, G) Differential expression of negatively associated miRNAs from TCGA database. Red stars represent negatively correlated miRNAs of <italic toggle="yes">CSPP1</italic>. (H) A forest plot of the correlations between <italic toggle="yes">CSPP1</italic>-negatively associated miRNAs expression and survival probability, including OS, DSS, and PFI. * <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01, *** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0155">Besides CNAs, DNA methylation also affects gene expression <xref rid="b0230" ref-type="bibr">[46]</xref>. Promoter methylation was reduced with upregulated <italic toggle="yes">CSPP1</italic> expression in BRCA, HNSC, and READ, while it was increased with downregulated <italic toggle="yes">CSPP1</italic> expression in KIRC and LUSC from UALCAN portal (<xref rid="f0010" ref-type="fig">Fig. 2</xref>C; <xref rid="s0130" ref-type="sec">Fig. S2</xref>). <italic toggle="yes">CSPP1</italic> expression negatively correlated with DNA methylation from cBioPortal (<xref rid="f0010" ref-type="fig">Fig. 2</xref>D and <xref rid="s0130" ref-type="sec">Table S2</xref>).</p><p id="p0160">In addition to CNAs and DNA methylation, miRNAs also play important roles in regulating mRNA expression <xref rid="b0235" ref-type="bibr">[47]</xref>. The ENCORI portal was used to search for miRNAs negatively associated with <italic toggle="yes">CSPP1</italic>. These miRNAs were found in most cancers except for ACC (<xref rid="f0010" ref-type="fig">Fig. 2</xref>E; <xref rid="s0130" ref-type="sec">Table S3</xref>). We further conducted differential expression analyses of these miRNAs across 14 cancers with data using TCGA datasets. <italic toggle="yes">CSPP1</italic> upregulation was associated with the downregulation of miR-221-3p and miR-377-3p in BRCA; miR-145-5p and miR-125b-5p in STAD (<xref rid="f0010" ref-type="fig">Fig. 2</xref>F). Meanwhile, <italic toggle="yes">CSPP1</italic> downregulation may be affected by upregulation of miR-222-3p in KICH; miR-425-5p, miR-221-3p, miR-222-3p, miR-340-5p, miR-150-5p, miR-708-5p in KIRC; miR-135b-5p, miR-222-3p, miR-27a-3p, miR-708-5p in LUAD; miR-135b-5p in LUSC; miR-135a-5p in PRAD; miR-105-5p, miR-221-3p and miR-222-3p in THCA; miR-135b-5p and miR-27a-3p in UCEC (<xref rid="f0010" ref-type="fig">Fig. 2</xref>G). A prognosis-related forest plot indicated that in <italic toggle="yes">CSPP1</italic>-overexpressed cancers, downregulated miR-221-3p in BRCA caused favorable DSS and PFI; meanwhile, downregulated miR-145-5p and miR-125-5p in STAD had favorable OS, DSS, and PFI. Among cancers with low <italic toggle="yes">CSPP1</italic> expression, upregulated miR-425-5p, miR-221-3p, miR-222-3p, and miR-708-5p in KIRC caused poor OS, DSS, and PFI; whereas, upregulated miR-27a-3p in LUAD had poor OS and DSS (<xref rid="f0010" ref-type="fig">Fig. 2</xref>H; <xref rid="s0130" ref-type="sec">Fig. S3</xref>). Together, <italic toggle="yes">CSPP1</italic> dysregulation involves multi-dimensional mechanisms, including genetic alterations, DNA methylation, and miRNAs.</p></sec><sec id="s0080"><label>3.3</label><title>Phosphorylation of CSPP1 at specific sites may play a role in tumorigenesis, especially at Ser424</title><p id="p0165">With datasets available in BRCA, GBM, HNSC, KIRC, LIHC, LUAD, OV, PAAD, and UCEC, CSPP1 protein expression was significantly increased in LIHC, PAAD, and UCEC compared with normal tissues; meanwhile, it was decreased in BRCA and HNSC (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A; <xref rid="s0130" ref-type="sec">Fig. S4</xref>A).<fig id="f0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Phosphorylation of CSPP1 at specific sites may play a role in tumorigenesis, especially at Ser424. (A) Histograms of CSPP1 expression in nine types of the normal and primary tumors with significant differences using CPTAC samples from UALCAN portal. (B) The schematic diagram of CSPP1 phosphorylation sites. Red and blue words indicated high and low protein expression, respectively. (C) Histograms of the phosphorylation site of CSPP1 in normal and primary tumors with significant differences. <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 was considered statistically significant. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0170">Post-translational modification (PTM) is a key molecular mechanism associated with the activity of the protein <xref rid="b0240" ref-type="bibr">[48]</xref>. A higher S31 phosphorylation level was observed in BRCA, GBM, LIHC, and LUAD; meanwhile, a lower level was observed in KIRC and PAAD. S424 phosphorylation was increased in BRCA, HNSC, KIRC, and LIHC. S847 phosphorylation was increased in HNSC but decreased in PAAD. Increased S866 phosphorylation was observed in HNSC and LIHC but decreased in KIRC, LUAD, and PAAD. S885 phosphorylation was increased in LIHC and decreased in KIRC. S931 phosphorylation was increased in LIHC and decreased in KIRC and LUAD (<xref rid="f0015" ref-type="fig">Fig. 3</xref>B, C; <xref rid="s0130" ref-type="sec">Fig. S4</xref>B). No threonine or tyrosine phosphorylation was identified in these cancer types with UALCAN database. Together, these findings suggested that phosphorylation of CSPP1 at specific sites may play a role in tumorigenesis, especially at Ser424.</p></sec><sec id="s0085"><label>3.4</label><title>CSPP1 correlates with clinical features and outcomes in multiple cancers</title><p id="p0175">Thereafter, we investigated <italic toggle="yes">CSPP1</italic> expression at different pathologic stages, histologic grades, and molecular subtypes. <italic toggle="yes">CSPP1</italic> overexpression significantly correlated with advanced pathologic stage in READ, ACC, and KICH, and advanced histologic grade in HNSC and LIHC; however, high <italic toggle="yes">CSPP1</italic> expression correlated with low histologic grade in KIRC (<xref rid="f0020" ref-type="fig">Fig. 4</xref>A-D). In addition, <italic toggle="yes">CSPP1</italic> expression significantly differed with respect to molecular subtypes in BRCA, COAD, ESCA, LGG, LIHC, READ, LUSC, and UCEC (<xref rid="f0020" ref-type="fig">Fig. 4</xref>E, F). However, no association was observed in other cancers (<xref rid="s0130" ref-type="sec">Fig. S5</xref>).<fig id="f0020" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><italic toggle="yes">CSPP1</italic> correlates with clinical features and outcomes in multiple cancers. (A-D) Violin plots of correlation between <italic toggle="yes">CSPP1</italic> expression and pathologic stage (A, B) and histologic grade (C, D) from TCGA database with significant differences using Kruskal-Wallis test. (E, F) Violin plots of correlation between <italic toggle="yes">CSPP1</italic> expression and molecular subtype with significant differences from TISIDB portal. <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 was considered as a statistical difference between the two groups. (G) A forest plot of the correlations between <italic toggle="yes">CSPP1</italic> expression and survival probability, including OS, DSS, and PFI. (H) A forest plot of univariate and multivariate Cox regression analyses with OS in LGG from TCGA database. <italic toggle="yes">p</italic> represented the overall difference. * <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01, *** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001. (I) Identification of <italic toggle="yes">CSPP1</italic> as an independent risk factor in LGG. The upper portion scatters plot was survival time and survival status according to <italic toggle="yes">CSPP1</italic> expression, and the middle portion scatters plot was risk score. (J) Construction of a prognostic nomogram in LGG. (K) Nomogram calibration analysis with prognostic data in LGG. C-index&#160;&gt;&#160;0.9 indicated highly accuracy, 0.9&#160;&#8805;&#160;C-index&#160;&gt;&#160;0.7 was median, and 0.7&#160;&#8805;&#160;C-index&#160;&gt;&#160;0.5 was low.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0180">To monitor the clinical outcomes of <italic toggle="yes">CSPP1</italic> differential expression, a Cox regression analysis was performed with respect to patients&#8217; prognoses. Results indicated that in <italic toggle="yes">CSPP1-</italic>upregulated cancers, <italic toggle="yes">CSPP1</italic> overexpression was associated with poor OS, DSS, and PFI in LGG and LIHC. In <italic toggle="yes">CSPP1</italic>-downregulated cancers, decreased <italic toggle="yes">CSPP1</italic> expression was associated with favorable OS, DSS, and PFI in ACC (<xref rid="f0020" ref-type="fig">Fig. 4</xref>G; <xref rid="s0130" ref-type="sec">Fig. S6</xref>). Overall, excessive <italic toggle="yes">CSPP1</italic> expression is unfavorable in several cancer types, especially LGG, LIHC, and ACC.</p><p id="p0185">To further evaluate whether <italic toggle="yes">CSPP1</italic> was an independent risk factor for prognosis, we used LGG as an example (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 for OS, DSS, and PFI). The baseline datasheet showed that <italic toggle="yes">CSPP1</italic> was significantly correlated with the WHO grade, IDH status, 1p/19q co-deletion, and histological type (<xref rid="s0130" ref-type="sec">Table S4</xref>). Univariate Cox regression analyses further indicated that <italic toggle="yes">CSPP1</italic> correlated with poor prognosis. Furthermore, multivariate Cox regression analyses confirmed that <italic toggle="yes">CSPP1</italic> overexpressed as an independent factor associated with OS, DSS, and PFI (<xref rid="f0020" ref-type="fig">Fig. 4</xref>H, I; <xref rid="s0130" ref-type="sec">Fig. S7</xref>A, B, E, F). Based on the multivariate Cox regression analyses, nomogram prediction models were established (<xref rid="f0020" ref-type="fig">Fig. 4</xref>J; <xref rid="s0130" ref-type="sec">Fig. S7</xref>C, G). We performed calibration analysis on the nomograms to verify the validity of the predictive models. The C-indexes of OS, DSS, and PFI indicate median accuracy (<xref rid="f0020" ref-type="fig">Fig. 4</xref>K; <xref rid="s0130" ref-type="sec">Fig. S7</xref>D, H). These results confirmed <italic toggle="yes">CSPP1</italic> as an independent risk factor for LGG survival.</p></sec><sec id="s0090"><label>3.5</label><title>Functional enrichment indicates CSPP1 is potentially associated with ferroptosis and TME in LGG</title><p id="p0190">Based on its unfavorable prognosis, LGG patients were divided into high and low <italic toggle="yes">CSPP1</italic> expression groups, and mRNA expression patterns were compared. A total of 14 upregulated and 67 downregulated genes were identified (<xref rid="f0025" ref-type="fig">Fig. 5</xref>A). Correlations between <italic toggle="yes">CSPP1</italic> and the top 20 DEGs were visualized by a heatmap (<xref rid="f0025" ref-type="fig">Fig. 5</xref>B; <xref rid="s0130" ref-type="sec">Table S5</xref>).<fig id="f0025" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Functional enrichment indicates that <italic toggle="yes">CSPP1</italic> is potentially associated with ferroptosis and TME in LGG. (A) A volcano plot of <italic toggle="yes">CSPP1</italic>-related DEGs in LGG. Red and blue points indicated upregulated and downregulated genes, respectively. (B) A heatmap of correlation between <italic toggle="yes">CSPP1</italic> and the top 20 DEGs. *** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001. (C) Bubble plots of GO enrichment. The X-axis represents the ratio of these DEGs, and the Y-axis represents the categories of DEGs. (D) Ridge plots of GSEA enrichment. <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 was considered the meaningful pathway. Red and blue indicated immune-related pathways and ferroptosis-related metabolic pathways, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0195">GO and GSEA analyses were performed to investigate the functional mechanisms of <italic toggle="yes">CSPP1</italic>. <italic toggle="yes">CSPP1</italic>-related DEGs were enriched in (i) CCs: presynapse, transport vesicle, and synaptic membrane; (ii) MFs: passive transmembrane transporter activity, channel activity, and substrate-specific channel activity; and (iii) BPs: signal release, vesicle-mediated transport in synapse, and regulation of transporter activity (<xref rid="f0025" ref-type="fig">Fig. 5</xref>C; <xref rid="s0130" ref-type="sec">Table S6</xref>). GSEA was also used to identify <italic toggle="yes">CSPP1</italic>-associated pathways. The results suggested that, in hallmark gene sets, <italic toggle="yes">CSPP1</italic>-related DEGs were positively related to cell cycle-related pathways (E2F targets, G2/M checkpoint, and mitotic spindle), cancer-related pathways (Notch signaling and TGF-&#946; signaling), EMT, and inflammatory response; meanwhile, they were negatively related to KRAS signaling DN, ferroptosis-related metabolic pathways (fatty acid metabolism, cholesterol homeostasis, and oxidative phosphorylation). For GO and KEGG gene sets, <italic toggle="yes">CSPP1</italic>-related DEGs were positively associated with cell cycle-related pathways (cell cycle checkpoint, chromosome segregation, and microtubule cytoskeleton organization involved in mitosis), cancer-related pathways (Notch signaling pathway, TGF-&#946; signaling pathway, and pathways in cancer), stromal-related pathway (ECM structural constituent, extracellular structure organization, ECM receptor interaction, and focal adhesion), and immune-related pathways (B cell-mediated immunity, adaptive immune response, positive regulation of T cell proliferation, T cell activation involved in immune response, complement and coagulation cascades, intestinal immune network for IgA production, cytosolic DNA sensing pathway, and toll-like receptor signaling pathway); meanwhile, they were negatively associated with ferroptosis-related metabolic pathways (steroid metabolic process, steroid biosynthetic process, response to metal ion, terpenoid backbone biosynthesis, and oxidative phosphorylation) (<xref rid="f0025" ref-type="fig">Fig. 5</xref>D; <xref rid="s0130" ref-type="sec">Table S7</xref>). These findings implied that <italic toggle="yes">CSPP1</italic> may be involved in ferroptosis and TME.</p></sec><sec id="s0095"><label>3.6</label><title>CSPP1 dysregulates ferroptosis in LGG and other cancer types</title><p id="p0200"><italic toggle="yes">TP53</italic> is the most commonly mutated gene associated with cancers and its mutations have been reported to be closely associated with ferroptosis <xref rid="b0245" ref-type="bibr">[49]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0255" ref-type="bibr">[51]</xref>, <xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0270" ref-type="bibr">[54]</xref>, <xref rid="b0275" ref-type="bibr">[55]</xref>. To verify the correlation between <italic toggle="yes">TP53</italic> mutation and <italic toggle="yes">CSPP1</italic> expression, somatic mutation analysis was performed according to <italic toggle="yes">CSPP1</italic> expression in LGG. From the oncoplot, higher frequencies of <italic toggle="yes">TP53</italic> and <italic toggle="yes">ATRX</italic> mutations and lower frequencies of <italic toggle="yes">CIC</italic>, <italic toggle="yes">FUBP1</italic>, <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">IDH2</italic>, and <italic toggle="yes">ZBTB20</italic> mutations were observed in the high <italic toggle="yes">CSPP1</italic> expression group (<xref rid="f0030" ref-type="fig">Fig. 6</xref>A, B). However, no association between <italic toggle="yes">ATRX</italic>, <italic toggle="yes">CIC</italic>, <italic toggle="yes">FUBP1</italic>, <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">IDH2</italic>, and <italic toggle="yes">ZBTB20</italic> mutations and ferroptosis has been reported.<fig id="f0030" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><italic toggle="yes">CSPP1</italic> dysregulates ferroptosis in LGG and other cancer types. (A) Oncoplot of somatic mutant landscape in high and low <italic toggle="yes">CSPP1</italic> expression groups in LGG. * <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01, *** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001. (B) Histograms of gene mutants comparison in high and low <italic toggle="yes">CSPP1</italic> expression groups by chisq.test with significant differences. (C, D) Heatmaps of correlation between <italic toggle="yes">CSPP1</italic> and FAGs and ferroptosis-associated scores. Dot size together with transition color represented the degree of correlation. The larger the dot, the stronger the correlation. Red and blue dots represented positive and negative correlations, respectively. * <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01. (E) Histograms of ferroptosis scores between high and low <italic toggle="yes">CSPP1</italic> expression groups from TCGA database. <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 was considered statistically significant. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0205">To further confirm the correlation between <italic toggle="yes">CSPP1</italic> and ferroptosis, 30 ferroptosis-associated genes (FAGs) were extracted from KEGG, including 18 ferroptosis-driver genes (FDGs) of <italic toggle="yes">ACSL1</italic>, <italic toggle="yes">ACSL4</italic>, <italic toggle="yes">ACSL6</italic>, <italic toggle="yes">ALOX15</italic>, <italic toggle="yes">ATG5</italic>, <italic toggle="yes">ATG7</italic>, <italic toggle="yes">FTL</italic>, <italic toggle="yes">LPCAT3</italic>, <italic toggle="yes">MAP1LC3A</italic>, <italic toggle="yes">MAP1LC3B</italic>, <italic toggle="yes">NCOA4</italic>, <italic toggle="yes">SAT1</italic>, <italic toggle="yes">SLC39A14</italic>, <italic toggle="yes">TF</italic>, <italic toggle="yes">TFRC</italic>, <italic toggle="yes">TP53</italic>, <italic toggle="yes">VDAC2</italic>, <italic toggle="yes">VDAC3</italic> and 12 ferroptosis-suppressor genes (FSGs) of <italic toggle="yes">ACSL3</italic>, <italic toggle="yes">FTH1</italic>, <italic toggle="yes">FTMT</italic>, <italic toggle="yes">GCLC</italic>, <italic toggle="yes">GCLM</italic>, <italic toggle="yes">GPX4</italic>, <italic toggle="yes">GSS</italic>, <italic toggle="yes">HMOX1</italic>, <italic toggle="yes">PCBP1</italic>, <italic toggle="yes">SLC3A2</italic>, <italic toggle="yes">SLC7A11</italic>, <italic toggle="yes">SLC40A1</italic>
<xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0295" ref-type="bibr">[59]</xref>. We found that <italic toggle="yes">CSPP1</italic> positively correlated with most FAGs, but negatively correlated with two FDGs of <italic toggle="yes">FTL</italic>, <italic toggle="yes">MAP1LC3A</italic>, and three FSGs of <italic toggle="yes">FTH1</italic>, <italic toggle="yes">GPX4</italic>, and <italic toggle="yes">HMOX1</italic> (<xref rid="f0030" ref-type="fig">Fig. 6</xref>C; <xref rid="s0130" ref-type="sec">Table S8</xref>).</p><p id="p0210">Next, the overall scores of driver genes and suppressor genes were calculated by the ssGSEA algorithm, and the ferroptosis score obtained from driver score minus suppressor score was used to evaluate whether the function of <italic toggle="yes">CSPP1</italic> was to activated or inhibited ferroptosis in cancers. The gene set and its corresponding algorithm have been proved to be able to predict ferroptosis status <xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0295" ref-type="bibr">[59]</xref>. In <italic toggle="yes">CSPP1</italic>-upregulated cancers, <italic toggle="yes">CSPP1</italic> positively correlated with ferroptosis score in LAML; meanwhile, negative correlations were observed in BRCA, GBM, LGG, LIHC, and THYM. In <italic toggle="yes">CSPP1</italic>-downregulated cancers, positive correlations were exhibited in ACC and LUAD, while negative correlations existed in KIRC, OV, and PRAD (<xref rid="f0030" ref-type="fig">Fig. 6</xref>D; <xref rid="s0130" ref-type="sec">Table S8</xref>). These tumor samples were further divided into high and low <italic toggle="yes">CSPP1</italic> expression groups, and the ferroptosis score was further compared between the two groups. From the histogram, as an antitumor mechanism, ferroptosis was overall inhibited in pan-cancer (ferroptosis score&#160;&lt;&#160;1), except for LAML. Lower scores represented lower ferroptosis levels in BRCA, COAD, GBM, LGG, LIHC, THYM, OV, and PRAD and higher scores represented higher ferroptosis levels in LAML and ACC were observed in the high <italic toggle="yes">CSPP1</italic> expression group (<xref rid="f0030" ref-type="fig">Fig. 6</xref>E; <xref rid="s0130" ref-type="sec">Table S8</xref>). Thus, our findings revealed that <italic toggle="yes">CSPP1</italic> dysregulates ferroptosis in LGG and other cancer types.</p></sec><sec id="s0100"><label>3.7</label><title>CSPP1-associated tumors are infiltrated in different TMEs, improving ICB therapeutic efficacy in specific cancers</title><p id="p0215">Functional enrichment analysis also implied that <italic toggle="yes">CSPP1</italic> may regulate the TME by influencing the immune response and stromal response. Therefore, we performed a pan-cancer analysis of the correlation between <italic toggle="yes">CSPP1</italic> and these two components. We first focused on <italic toggle="yes">CSPP1</italic> and 24 types of immune cells using the ssGSEA algorithm. The results showed that <italic toggle="yes">CSPP1</italic> negatively correlated with most immune cells across cancers but positively correlated with T helper cells, central memory T (Tcm) cells, and T helper 2 (Th2) cells. Of note, Tcm cells are also immunosuppressive cells. Next, stromal cell infiltration was assessed using the XCELL algorithm from the TIMER2 portal, mainly including CAF cells and endothelial cells <xref rid="b0300" ref-type="bibr">[60]</xref>. There was a positive correlation between <italic toggle="yes">CSPP1</italic> and CAFs in HNSC, LGG, LIHC, THYM, KICH, SKCM, and THCA, whereas an inverse correlation was observed in STAD, KIRC, LUSC, and TGCT. Moreover, <italic toggle="yes">CSPP1</italic> was negatively correlated with endothelial cells in BRCA, DLBC, LGG, LIHC, STAD, THYM, PRAD, TGCT, and UCEC, whereas a positive correlation was noted in OV. Thereafter, we comprehensively calculated the TME score using the ESTIMATE package. <italic toggle="yes">CSPP1</italic> was negatively associated with the stromal score, immune score, and ESTIMATE score in most cancers, while positively associated with these scores in LGG (<xref rid="f0035" ref-type="fig">Fig. 7</xref>A; <xref rid="s0130" ref-type="sec">Table S9</xref>). To sum up, <italic toggle="yes">CSPP1</italic> comprehensively regulates the TME from both immune cell infiltration and stromal cell infiltration.<fig id="f0035" position="float" orientation="portrait"><label>Fig. 7</label><caption><p><italic toggle="yes">CSPP1</italic>-associated tumors are infiltrated in different TMEs, improving ICB therapeutic efficacy in specific cancers. (A) A heatmap of correlations between <italic toggle="yes">CSPP1</italic> and 24 types of immune cells from TCGA database, CAFs and endothelial cells from TIMER2 portal using XCELL algorithm, and TME scores from TCGA database using the ssGSEA algorithm. (B) A heatmap of correlations between <italic toggle="yes">CSPP1</italic> and immunomodulators, including MHC molecules, immune stimulator genes, and immune inhibitor genes from TCGA database. (C) A heatmap of correlations between <italic toggle="yes">CSPP1</italic> and immune checkpoints from the TIMER2 portal. (D) A heatmap of correlations between <italic toggle="yes">CSPP1</italic> and TMB score, MSI score from TCGA database. Dot size together with transition color represented the degree of correlation. The larger the dot, the stronger the correlation. Red and blue dots represented positive and negative correlation, respectively. * <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, ** <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01. (E, F) Histograms of <italic toggle="yes">CSPP1</italic>-associated ICB therapeutic effect between high and low <italic toggle="yes">CSPP1</italic> expression groups from TCGA database by TIDE algorithm with a significant difference. A low score indicated good efficacy. <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 was considered statistically significant. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p><p id="p0220">To further study the regulatory mechanism of <italic toggle="yes">CSPP1</italic>-related tumor infiltration, correlations between <italic toggle="yes">CSPP1</italic> and three types of immunomodulators were investigated with TCGA datasets <xref rid="b0305" ref-type="bibr">[61]</xref>. <italic toggle="yes">CSPP1</italic> negatively correlated with MHCs and positively with immune stimulators and immune inhibitors in most cancers (<xref rid="f0035" ref-type="fig">Fig. 7</xref>B; <xref rid="s0130" ref-type="sec">Table S9</xref>). Among immune inhibitors, <italic toggle="yes">CD274</italic> (PD-L1), <italic toggle="yes">CTLA4, HAVCR2, LAG3, PDCD1</italic> (PD1), <italic toggle="yes">PDCD1LG2</italic> (PD-L2), <italic toggle="yes">TIGIT</italic>, and <italic toggle="yes">SIGLEC15</italic> are known immune checkpoints responsible for tumor immune escape. Combined with these immune checkpoint results and subsequent analysis using the TIMER2 portal, it was further confirmed that <italic toggle="yes">CSPP1</italic> was positively correlated with immune checkpoints in BRCA, DLBC, ESCA, HNSC, LGG, LIHC, PAAD, READ, KICH, and KIRC, and negatively correlated with them in COAD, LAML, CESC, THCA, and UCEC (<xref rid="f0035" ref-type="fig">Fig. 7</xref>B, C; <xref rid="s0130" ref-type="sec">Table S9</xref>).</p><p id="p0225">TMB and MSI are two emerging biomarkers associated with immunotherapy response. Tumor cells with high TMB or MSI scores have strong antigenicity and more neoantigens, thus promoting immune cell infiltration. Results showed that <italic toggle="yes">CSPP1</italic> positively correlated with TMB in LGG, STAD, and PRAD, but inversely correlated with it in COAD, LIHC, THCA, and UCEC. The correlation between <italic toggle="yes">CSPP1</italic> and MSI was then investigated. LGG, READ, STAD, LUAD, and LUSC showed positive correlations, whereas DLBC presented a negative correlation (<xref rid="f0035" ref-type="fig">Fig. 7</xref>D; <xref rid="s0130" ref-type="sec">Table S9</xref>).</p><p id="p0230">Tumor immunotherapy is a treatment that controls and eliminates tumors by reactivating and maintaining the tumor-immune cycle and restoring the normal antitumor immune response, including ICB and cell therapy. The effectiveness of ICB therapy depends not only on immune cell infiltration but also on immune checkpoints, TMB, and MSI. The close correlations between <italic toggle="yes">CSPP1</italic> and immune checkpoints, TMB, and MSI implied that these <italic toggle="yes">CSPP1</italic>-associated tumor patients may respond well to immunotherapy. Therefore, the TIDE algorithm was used to predict the therapeutic effect of ICB from TCGA database. Results revealed that in <italic toggle="yes">CSPP1</italic>-upregulated cancers, the high <italic toggle="yes">CSPP1</italic> expression group exhibited a lower TIDE score, including BRCA, DLBC, LGG, and STAD; meanwhile, the low <italic toggle="yes">CSPP1</italic> expression group exhibited a lower TIDE score in LIHC (<xref rid="f0035" ref-type="fig">Fig. 7</xref>E; <xref rid="s0130" ref-type="sec">Fig. S8</xref>A). In <italic toggle="yes">CSPP1</italic>-downregulated cancers, the high <italic toggle="yes">CSPP1</italic> expression group exhibited a lower TIDE score, including CESC, KIRC, LUSC, PRAD, SKCM, TGCT, THCA, and UCES (<xref rid="f0035" ref-type="fig">Fig. 7</xref>F; <xref rid="s0130" ref-type="sec">Fig. S8</xref>B). It is suggested that these patients with low TIDE scores may benefit from ICB therapy.</p></sec></sec><sec id="s0105"><label>4</label><title>Discussion</title><p id="p0235">Cancer is the leading cause of morbidity and mortality worldwide. <italic toggle="yes">CSPP1</italic> is a centrosome and microtubule-binding protein that plays a role in cell cycle-dependent cytoskeleton organization and cilia formation. Although there is increasing evidence that <italic toggle="yes">CSPP1</italic> may play a role in tumorigenesis, its specific role across different cancers remains unclear. This study systematically analyzed <italic toggle="yes">CSPP1</italic> expression and demonstrated that its aberrant expression in 27 cancer types is driven by multi-dimensional mechanisms. <italic toggle="yes">CSPP1</italic> correlates with clinical features and serves as a potential diagnostic and prognostic biomarker as well as the target for ferroptosis-based drug therapy and immunotherapy.</p><p id="p0240">To explore how <italic toggle="yes">CSPP1</italic> influences the progress and prognosis of cancer, its effects on ferroptosis and TME were studied. Function enrichment demonstrated that <italic toggle="yes">CSPP1</italic> was involved in ferroptosis-related metabolic pathways. Mutation analyses further indicated that <italic toggle="yes">CSPP1</italic> was closely associated with <italic toggle="yes">TP53</italic> mutation, which has been reported to be associated with cancer and ferroptosis, thus speculating that <italic toggle="yes">CSPP1</italic> might correlate with ferroptosis. At present, studies on ferroptosis-associated gene mutations are mainly limited to the oncogenes and tumor suppressor genes, including oncogenes of <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">NEDD4</italic>, <italic toggle="yes">VDAC2/3</italic>, <italic toggle="yes">DJ1</italic>, <italic toggle="yes">PDK4</italic>, and tumor suppressor genes of <italic toggle="yes">TP53</italic>, <italic toggle="yes">BAP1</italic>, <italic toggle="yes">KEAP1, ARF</italic>. Activating mutations in oncogenes and inactivating mutations in tumor suppressor genes regulate the expression of FAGs, and generally tend to inhibit ferroptosis and promote tumor progression. However, mutations in tumor suppressors of the <italic toggle="yes">E-cadherin-NF2-Hippo</italic> axis, <italic toggle="yes">VHL</italic>, and oncogenes of <italic toggle="yes">EGFR</italic> and <italic toggle="yes">IDH1</italic> render cancer cells vulnerable to ferroptosis in one or more cancer types <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0315" ref-type="bibr">[63]</xref>. Our correlation analyses between <italic toggle="yes">CSPP1</italic> and FAGs and ferroptosis-associated scores further confirmed that <italic toggle="yes">CSPP1</italic> was indeed involved in the regulation of ferroptosis in pan-cancer. Combined with the prognostic data, we believed that in <italic toggle="yes">CSPP1</italic>-upregulated cancers, <italic toggle="yes">CSPP1</italic> overexpression inhibited ferroptosis, including BRCA, GBM, LGG, LIHC, and THYM, thus promoting tumor cell growth and leading to poor prognoses in BRCA, LGG, and LIHC. Meanwhile, its overexpression promoted ferroptosis in LAML and led to cancer with a good prognosis. These results were consistent with the progression and prognosis results of <italic toggle="yes">CSPP1</italic>. However, there were some exceptions. For example, patients with lower expression of <italic toggle="yes">CSPP1</italic> showed lower ferroptosis level but better prognosis in ACC, and higher ferroptosis levels but still led to cancer in OV and PRAD. Thus, there should be other mechanisms influencing the progression and prognosis of these cancers. For <italic toggle="yes">CSPP1</italic>-associated tumors with suppressed ferroptosis, drug-induced ferroptosis through the <italic toggle="yes">CSPP1</italic>-FDGs or <italic toggle="yes">CSPP1-</italic>FSGs axis may inhibit tumor progression and thus improve prognosis. Therefore, the possibility of drug therapy for <italic toggle="yes">CSPP1</italic>-associated tumor patients by regulating ferroptosis is proposed.</p><p id="p0245">In addition to regulating ferroptosis, <italic toggle="yes">CSPP1</italic> may have a regulatory role in the TME by affecting EMT, stromal-related pathways, and immune-related pathways. In recent years, an increasing number of studies have linked microtubule-associated genes to immune infiltration. High expression of Targeting Protein for Xenopus kinesin-like protein 2 (<italic toggle="yes">TPX2</italic>) and Tubulin alpha-1C chain (<italic toggle="yes">TUBA1C</italic>) increases immune cell infiltration in LIHC, LUAD, and LGG, respectively, and is associated with poor prognosis <xref rid="b0320" ref-type="bibr">[64]</xref>, <xref rid="b0325" ref-type="bibr">[65]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>. A high level of microtubule-associated protein <italic toggle="yes">Tau</italic> is inversely correlated with the vascular and immune contents, delaying tumor growth in gliomas <xref rid="b0335" ref-type="bibr">[67]</xref>. Increased expression of microtubule interacting and trafficking domain containing 1 (<italic toggle="yes">MITD1</italic>) indicates a poor prognosis with decreased NK cell infiltration in LIHC and increased CD8+ T cells infiltration in KIRC <xref rid="b0340" ref-type="bibr">[68]</xref>, <xref rid="b0345" ref-type="bibr">[69]</xref>. Spindle and kinetochore-associated protein (<italic toggle="yes">Ska</italic>) complex negatively and positively correlate with immune cell infiltration in BRCA and LIHC, respectively <xref rid="b0350" ref-type="bibr">[70]</xref>, <xref rid="b0355" ref-type="bibr">[71]</xref>. In our study, <italic toggle="yes">CSPP1</italic> comprehensively regulated the TME from both immune cell infiltration and stromal cell infiltration. <italic toggle="yes">CSPP1</italic> was negatively correlated with immune scores, stromal scores, and TME scores for most cancers. Moreover, it was also negatively correlated with MHCs and positively associated with immune stimulators and immune inhibitors, including immune checkpoints. <italic toggle="yes">CSPP1</italic> expression also significantly correlated with TMB and MSI in specific cancers. ICB therapy prediction confirmed that these cancer patients could benefit from ICB therapy, thus promoting a favorable prognosis. Specifically, in <italic toggle="yes">CSPP1</italic>-upregulated cancers, low TME scores and high levels of immune checkpoints expression indicated immune infiltration was greatly suppressed, leading to tumor growth and poor prognosis. Therefore, ICB therapy promoting immune infiltration is effective for patients in the high <italic toggle="yes">CSPP1</italic> expression group of BRCA, DLBC, LGG, and STAD, but more effective for patients in the low <italic toggle="yes">CSPP1</italic> expression group of LIHC. In <italic toggle="yes">CSPP1</italic>-downregulated cancer, low <italic toggle="yes">CSPP1</italic> expression had higher levels of immune cell infiltration and lower levels of immune checkpoints expression, thus these cancers themselves were in a favorable prognostic immune microenvironment, and ICB therapy may be more effective for the early treatment of these patients, including CESC, KIRC, LUSC, PRAD, SKCM, TGCT, THCA, and UCEC.</p><p id="p0250">However, several limitations still remain. At present, our study on the regulation of <italic toggle="yes">CSPP1</italic> on ferroptosis and TME, as well as the subsequent potential drug treatment and ICB therapy are limited to bioinformatics, which provides a reference to basic experiments, but basic experiments are still necessary for follow-up research. In addition, the relatively small sample size is also one of the main reasons for data deviation. For example, as described above, the regulation of <italic toggle="yes">CSPP1</italic> expression involves multiple factors, which leads to the inconsistency between any individual factor and <italic toggle="yes">CSPP1</italic> expression, and the small sample size increases this inconsistency. In addition, the inconsistent expression between <italic toggle="yes">CSPP1</italic> mRNA and protein is the same case. Therefore, further basic experiments and more clinical samples are required to explore the direct functional mechanism of <italic toggle="yes">CSPP1</italic> affecting cancer progression and prognosis through ferroptosis and TME function.</p></sec><sec id="s0110"><label>5</label><title>Conclusion</title><p id="p0255">In conclusion, our study is the first to demonstrate that <italic toggle="yes">CSPP1</italic> is a potential diagnostic and prognostic biomarker associated with ferroptosis and TME, providing a new target for ferroptosis-based drug therapy and immunotherapy in specific cancer types.</p></sec><sec id="s0115"><title>Author contributions</title><p id="p0260">SZ contributed to the conception of the study. WW designed the study and wrote the manuscript. WW, JZ, YW, and YX had full access to all of the data in the study and take responsibility for the integrity of the data. WW, JZ, YW, and YX performed the statistical analyses. SZ obtained funding. All authors contributed to the article and approved the submitted version.</p></sec><sec id="s0120"><title>Funding information</title><p id="p0265">This work was supported by the <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (81773242), <funding-source id="gp010"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004731</institution-id><institution>Zhejiang Provincial Natural Science Foundation of China</institution></institution-wrap></funding-source> (LY19H160032), and <funding-source id="gp015">Major Project of Hangzhou Science and Technology Bureau</funding-source> (20180417A01).</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0270">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name></person-group><article-title>Hallmarks of cancer: new dimensions</article-title><source>Cancer Discov</source><volume>12</volume><year>2022</year><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">35022204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-21-1059</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Stockwell</surname><given-names>B.R.</given-names></name></person-group><article-title>The hallmarks of ferroptosis</article-title><source>Ann Rev Cancer Biol</source><volume>3</volume><year>2019</year><fpage>35</fpage><lpage>54</lpage></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Moujalled</surname><given-names>D.</given-names></name><name name-style="western"><surname>Strasser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liddell</surname><given-names>J.R.</given-names></name></person-group><article-title>Molecular mechanisms of cell death in neurological diseases</article-title><source>Cell Death Differ</source><volume>28</volume><year>2021</year><fpage>2029</fpage><lpage>2044</lpage><pub-id pub-id-type="pmid">34099897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-021-00814-y</pub-id><pub-id pub-id-type="pmcid">PMC8257776</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name name-style="western"><surname>Stockwell</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Friedmann Angeli</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bayir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease</article-title><source>Cell</source><volume>171</volume><year>2017</year><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">28985560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.09.021</pub-id><pub-id pub-id-type="pmcid">PMC5685180</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Green</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Gijon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>P.D.</given-names></name><etal/></person-group><article-title>CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy</article-title><source>Nature</source><volume>569</volume><year>2019</year><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">31043744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1170-y</pub-id><pub-id pub-id-type="pmcid">PMC6533917</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Linghu</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>M.C.</given-names></name></person-group><article-title>Ferroptosis: a promising target for cancer immunotherapy</article-title><source>Am J Cancer Res</source><volume>11</volume><year>2021</year><fpage>5856</fpage><lpage>5863</lpage><pub-id pub-id-type="pmid">35018229</pub-id><pub-id pub-id-type="pmcid">PMC8727800</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name name-style="western"><surname>Turley</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Cremasco</surname><given-names>V.</given-names></name><name name-style="western"><surname>Astarita</surname><given-names>J.L.</given-names></name></person-group><article-title>Immunological hallmarks of stromal cells in the tumour microenvironment</article-title><source>Nat Rev Immunol</source><volume>15</volume><year>2015</year><fpage>669</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">26471778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3902</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Bruni</surname><given-names>D.</given-names></name><name name-style="western"><surname>Angell</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Galon</surname><given-names>J.</given-names></name></person-group><article-title>The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy</article-title><source>Nat Rev Cancer</source><volume>20</volume><year>2020</year><fpage>662</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">32753728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-020-0285-7</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kryczek</surname><given-names>I.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity</article-title><source>Nat Immunol</source><volume>22</volume><year>2021</year><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">33767425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-021-00888-3</pub-id><pub-id pub-id-type="pmcid">PMC8026726</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name></person-group><article-title>Immune regulation in the tumor microenvironment and its relevance in cancer therapy</article-title><source>Cell Mol Immunol</source><volume>19</volume><year>2022</year><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">34992273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-021-00738-0</pub-id><pub-id pub-id-type="pmcid">PMC8752764</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Patzke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hauge</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sioud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Finne</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Sivertsen</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization</article-title><source>Oncogene</source><volume>24</volume><year>2005</year><fpage>1159</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">15580290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1208267</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Patzke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stokke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aasheim</surname><given-names>H.C.</given-names></name></person-group><article-title>CSPP and CSPP-L associate with centrosomes and microtubules and differently affect microtubule organization</article-title><source>J Cell Physiol</source><volume>209</volume><year>2006</year><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">16826565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.20725</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Asiedu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name></person-group><article-title>Centrosome/spindle pole-associated protein regulates cytokinesis via promoting the recruitment of MyoGEF to the central spindle</article-title><source>Mol Biol Cell</source><volume>20</volume><year>2009</year><fpage>1428</fpage><lpage>1440</lpage><pub-id pub-id-type="pmid">19129481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.E08-01-0001</pub-id><pub-id pub-id-type="pmcid">PMC2649278</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mitotic protein CSPP1 interacts with CENP-H protein to coordinate accurate chromosome oscillation in mitosis</article-title><source>J Biol Chem</source><volume>290</volume><year>2015</year><fpage>27053</fpage><lpage>27066</lpage><pub-id pub-id-type="pmid">26378239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M115.658534</pub-id><pub-id pub-id-type="pmcid">PMC4646392</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Frikstad</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Molinari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thoresen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramsbottom</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A CEP104-CSPP1 complex is required for formation of primary cilia competent in hedgehog signaling</article-title><source>Cell Rep</source><volume>28</volume><year>2019</year><comment>1907&#8211;22 e6</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2019.07.025</pub-id><pub-id pub-id-type="pmcid">PMC6702141</pub-id><pub-id pub-id-type="pmid">31412255</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Patzke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Redick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Warsame</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murga-Zamalloa</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>H.</given-names></name><etal/></person-group><article-title>CSPP is a ciliary protein interacting with Nephrocystin 8 and required for cilia formation</article-title><source>Mol Biol Cell</source><volume>21</volume><year>2010</year><fpage>2555</fpage><lpage>2567</lpage><pub-id pub-id-type="pmid">20519441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.E09-06-0503</pub-id><pub-id pub-id-type="pmcid">PMC2912343</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name name-style="western"><surname>Shearer</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Frikstad</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>J.</given-names></name><name name-style="western"><surname>McCloy</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The E3 ubiquitin ligase UBR5 regulates centriolar satellite stability and primary cilia</article-title><source>Mol Biol Cell</source><volume>29</volume><year>2018</year><fpage>1542</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">29742019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1091/mbc.E17-04-0248</pub-id><pub-id pub-id-type="pmcid">PMC6080653</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Latour</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Van De Weghe</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rusterholz</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Letteboer</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dysfunction of the ciliary ARMC9/TOGARAM1 protein module causes Joubert syndrome</article-title><source>J Clin Invest</source><volume>130</volume><year>2020</year><fpage>4423</fpage><lpage>4439</lpage><pub-id pub-id-type="pmid">32453716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI131656</pub-id><pub-id pub-id-type="pmcid">PMC7410078</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Omran</surname><given-names>T.</given-names></name><name name-style="western"><surname>Alsulaiman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alkuraya</surname><given-names>F.S.</given-names></name></person-group><article-title>Intrafamilial clinical heterogeneity of CSPP1-related ciliopathy</article-title><source>Am J Med Genet A</source><volume>167A</volume><year>2015</year><fpage>2478</fpage><lpage>2480</lpage><pub-id pub-id-type="pmid">25997910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.a.37175</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name name-style="western"><surname>Tuz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bachmann-Gagescu</surname><given-names>R.</given-names></name><name name-style="western"><surname>O'Day</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>K.</given-names></name><name name-style="western"><surname>Isabella</surname><given-names>C.R.</given-names></name><etal/></person-group><article-title>Mutations in CSPP1 cause primary cilia abnormalities and Joubert syndrome with or without Jeune asphyxiating thoracic dystrophy</article-title><source>Am J Hum Genet</source><volume>94</volume><year>2014</year><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24360808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2013.11.019</pub-id><pub-id pub-id-type="pmcid">PMC3882733</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name name-style="western"><surname>Shaheen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shamseldin</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Loucks</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Seidahmed</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mutations in CSPP1, encoding a core centrosomal protein, cause a range of ciliopathy phenotypes in humans</article-title><source>Am J Hum Genet</source><volume>94</volume><year>2014</year><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">24360803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2013.11.010</pub-id><pub-id pub-id-type="pmcid">PMC3882732</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name name-style="western"><surname>Akizu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Silhavy</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rosti</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fenstermaker</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Mutations in CSPP1 lead to classical Joubert syndrome</article-title><source>Am J Hum Genet</source><volume>94</volume><year>2014</year><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">24360807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2013.11.015</pub-id><pub-id pub-id-type="pmcid">PMC3882909</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Sternemalm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geimer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frikstad</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Schink</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Stokke</surname><given-names>T.</given-names></name><etal/></person-group><article-title>CSPP-L associates with the desmosome of polarized epithelial cells and is required for normal spheroid formation</article-title><source>PLoS ONE</source><volume>10</volume><year>2015</year><fpage>e0134789</fpage><pub-id pub-id-type="pmid">26241740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0134789</pub-id><pub-id pub-id-type="pmcid">PMC4524657</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name name-style="western"><surname>Sternemalm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Russnes</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Risberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nord</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Nuclear CSPP1 expression defined subtypes of basal-like breast cancer</article-title><source>Br J Cancer</source><volume>111</volume><year>2014</year><fpage>326</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">24901235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2014.297</pub-id><pub-id pub-id-type="pmcid">PMC4102947</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barroso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caramelo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Genomic profile of oral squamous cell carcinomas with an adjacent leukoplakia or with an erythroleukoplakia that evolved after the treatment of primary tumor: A report of two cases</article-title><source>Mol Med Rep</source><volume>16</volume><year>2017</year><fpage>6780</fpage><lpage>6786</lpage><pub-id pub-id-type="pmid">28901451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2017.7428</pub-id><pub-id pub-id-type="pmcid">PMC5865835</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lichtenberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hoadley</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Poisson</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics</article-title><source>Cell</source><volume>173</volume><year>2018</year><comment>400-16 e11</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2018.02.052</pub-id><pub-id pub-id-type="pmcid">PMC6066282</pub-id><pub-id pub-id-type="pmid">29625055</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name name-style="western"><surname>Vivian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Nothaft</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Ketchum</surname><given-names>C.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Toil enables reproducible, open source, big biomedical data analyses</article-title><source>Nat Biotechnol</source><volume>35</volume><year>2017</year><fpage>314</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">28398314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.3772</pub-id><pub-id pub-id-type="pmcid">PMC5546205</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Varambally</surname><given-names>S.</given-names></name><name name-style="western"><surname>Creighton</surname><given-names>C.J.</given-names></name></person-group><article-title>Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers</article-title><source>Nat Commun</source><volume>10</volume><year>2019</year><fpage>5679</fpage><pub-id pub-id-type="pmid">31831737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13528-0</pub-id><pub-id pub-id-type="pmcid">PMC6908580</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name name-style="western"><surname>Chandrashekar</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Bashel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Balasubramanya</surname><given-names>S.A.H.</given-names></name><name name-style="western"><surname>Creighton</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ponce-Rodriguez</surname><given-names>I.</given-names></name><etal/></person-group><article-title>UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses</article-title><source>Neoplasia</source><volume>19</volume><year>2017</year><fpage>649</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">28732212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2017.05.002</pub-id><pub-id pub-id-type="pmcid">PMC5516091</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.H.</given-names></name></person-group><article-title>starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data</article-title><source>Nucleic Acids Res</source><volume>42</volume><year>2014</year><fpage>D92</fpage><lpage>D97</lpage><pub-id pub-id-type="pmid">24297251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkt1248</pub-id><pub-id pub-id-type="pmcid">PMC3964941</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name name-style="western"><surname>Ru</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>S.S.W.</given-names></name><etal/></person-group><article-title>TISIDB: an integrated repository portal for tumor-immune system interactions</article-title><source>Bioinformatics</source><volume>35</volume><year>2019</year><fpage>4200</fpage><lpage>4202</lpage><pub-id pub-id-type="pmid">30903160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btz210</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>S.</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><volume>15</volume><year>2014</year><fpage>550</fpage><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.Y.</given-names></name></person-group><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><volume>16</volume><year>2012</year><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">22455463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmcid">PMC3339379</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name name-style="western"><surname>Mayakonda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Assenov</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Plass</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koeffler</surname><given-names>H.P.</given-names></name></person-group><article-title>Maftools: efficient and comprehensive analysis of somatic variants in cancer</article-title><source>Genome Res</source><volume>28</volume><year>2018</year><fpage>1747</fpage><lpage>1756</lpage><pub-id pub-id-type="pmid">30341162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.239244.118</pub-id><pub-id pub-id-type="pmcid">PMC6211645</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yarmus</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma</article-title><source>Aging (Albany NY)</source><volume>12</volume><year>2020</year><fpage>16514</fpage><lpage>16538</lpage><pub-id pub-id-type="pmid">32855362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103775</pub-id><pub-id pub-id-type="pmcid">PMC7485744</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name name-style="western"><surname>Hanzelmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Castelo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guinney</surname><given-names>J.</given-names></name></person-group><article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title><source>BMC Bioinf</source><volume>14</volume><year>2013</year><fpage>7</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-14-7</pub-id><pub-id pub-id-type="pmcid">PMC3618321</pub-id><pub-id pub-id-type="pmid">23323831</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name name-style="western"><surname>Yoshihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shahmoradgoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vegesna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Inferring tumour purity and stromal and immune cell admixture from expression data</article-title><source>Nat Commun</source><volume>4</volume><year>2013</year><fpage>2612</fpage><pub-id pub-id-type="pmid">24113773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms3612</pub-id><pub-id pub-id-type="pmcid">PMC3826632</pub-id></element-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name name-style="western"><surname>Bindea</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mlecnik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tosolini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kirilovsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Waldner</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer</article-title><source>Immunity</source><volume>39</volume><year>2013</year><fpage>782</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">24138885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2013.10.003</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name></person-group><article-title>Comprehensive analysis of the PD-L1 and immune infiltrates of m(6)A RNA methylation regulators in head and neck squamous cell carcinoma</article-title><source>Mol Ther Nucleic Acids</source><volume>21</volume><year>2020</year><fpage>299</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">32622331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2020.06.001</pub-id><pub-id pub-id-type="pmcid">PMC7332506</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name></person-group><article-title>Genomic analysis and clinical implications of immune cell infiltration in gastric cancer</article-title><source>Biosci Rep</source><volume>40</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20193308</pub-id><pub-id pub-id-type="pmcid">PMC7240200</pub-id><pub-id pub-id-type="pmid">32338286</pub-id></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name name-style="western"><surname>Bonneville</surname><given-names>R.</given-names></name><name name-style="western"><surname>Krook</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kautto</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Miya</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wing</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Landscape of microsatellite instability across 39 cancer types</article-title><source>JCO Precis Oncol</source><year>2017</year><fpage>2017</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.17.00073</pub-id><pub-id pub-id-type="pmcid">PMC5972025</pub-id><pub-id pub-id-type="pmid">29850653</pub-id></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name name-style="western"><surname>Thorsson</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bortone</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>The immune landscape of cancer</article-title><source>Immunity</source><volume>48</volume><year>2018</year><comment>812&#8211;30 e14</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2018.03.023</pub-id><pub-id pub-id-type="pmcid">PMC5982584</pub-id><pub-id pub-id-type="pmid">29628290</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response</article-title><source>Nat Med</source><volume>24</volume><year>2018</year><fpage>1550</fpage><lpage>1558</lpage><pub-id pub-id-type="pmid">30127393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0136-1</pub-id><pub-id pub-id-type="pmcid">PMC6487502</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy</article-title><source>Aging (Albany NY)</source><volume>12</volume><year>2020</year><fpage>3312</fpage><lpage>3339</lpage><pub-id pub-id-type="pmid">32091408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.102814</pub-id><pub-id pub-id-type="pmcid">PMC7066911</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name name-style="western"><surname>Zack</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Cherniack</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Saksena</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Pan-cancer patterns of somatic copy number alteration</article-title><source>Nat Genet</source><volume>45</volume><year>2013</year><fpage>1134</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">24071852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2760</pub-id><pub-id pub-id-type="pmcid">PMC3966983</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name name-style="western"><surname>Nishiyama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>M.</given-names></name></person-group><article-title>Navigating the DNA methylation landscape of cancer</article-title><source>Trends Genet</source><volume>37</volume><year>2021</year><fpage>1012</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">34120771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tig.2021.05.002</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name name-style="western"><surname>Dvinge</surname><given-names>H.</given-names></name><name name-style="western"><surname>Git</surname><given-names>A.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salmon-Divon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The shaping and functional consequences of the microRNA landscape in breast cancer</article-title><source>Nature</source><volume>497</volume><year>2013</year><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">23644459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12108</pub-id></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name name-style="western"><surname>Cuijpers</surname><given-names>S.A.G.</given-names></name><name name-style="western"><surname>Vertegaal</surname><given-names>A.C.O.</given-names></name></person-group><article-title>Guiding mitotic progression by crosstalk between post-translational modifications</article-title><source>Trends Biochem Sci</source><volume>43</volume><year>2018</year><fpage>251</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">29486978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2018.02.004</pub-id></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name name-style="western"><surname>Mendiratta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liarakos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cancer gene mutation frequencies for the U.S. population</article-title><source>Nat Commun</source><volume>12</volume><year>2021</year><fpage>5961</fpage><pub-id pub-id-type="pmid">34645806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-26213-y</pub-id><pub-id pub-id-type="pmcid">PMC8514428</pub-id></element-citation></ref><ref id="b0250"><label>50</label><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name></person-group><article-title>p53 in ferroptosis regulation: the new weapon for the old guardian</article-title><source>Cell Death Differ</source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-022-00943-y</pub-id><pub-id pub-id-type="pmcid">PMC9091200</pub-id><pub-id pub-id-type="pmid">35087226</pub-id></element-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Ferroptosis as a p53-mediated activity during tumour suppression</article-title><source>Nature</source><volume>520</volume><year>2015</year><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">25799988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14344</pub-id><pub-id pub-id-type="pmcid">PMC4455927</pub-id></element-citation></ref><ref id="b0260"><label>52</label><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Acetylation is crucial for p53-mediated ferroptosis and tumor suppression</article-title><source>Cell Rep</source><volume>17</volume><year>2016</year><fpage>366</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">27705786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.09.022</pub-id><pub-id pub-id-type="pmcid">PMC5227654</pub-id></element-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name name-style="western"><surname>Jennis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kung</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Budina-Kolomets</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leu</surname><given-names>J.I.</given-names></name><etal/></person-group><article-title>An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model</article-title><source>Genes Dev</source><volume>30</volume><year>2016</year><fpage>918</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">27034505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.275891.115</pub-id><pub-id pub-id-type="pmcid">PMC4840298</pub-id></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name name-style="western"><surname>Tarangelo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Magtanong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bieging-Rolett</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><etal/></person-group><article-title>p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells</article-title><source>Cell Rep</source><volume>22</volume><year>2018</year><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">29346757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2017.12.077</pub-id><pub-id pub-id-type="pmcid">PMC5791910</pub-id></element-citation></ref><ref id="b0275"><label>55</label><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity</article-title><source>Cell Rep</source><volume>20</volume><year>2017</year><fpage>1692</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">28813679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2017.07.055</pub-id></element-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>J.</given-names></name></person-group><article-title>FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations</article-title><source>Database (Oxford)</source><volume>2020</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/database/baaa021</pub-id><pub-id pub-id-type="pmcid">PMC7100629</pub-id><pub-id pub-id-type="pmid">32219413</pub-id></element-citation></ref><ref id="b0285"><label>57</label><mixed-citation publication-type="other" id="h0285">Liu Z, Zhao Q, Zuo ZX, Yuan SQ, Yu K, et al. Systematic analysis of the aberrances and functional implications of ferroptosis in cancer. iScience 2020; 23:101302.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2020.101302</pub-id><pub-id pub-id-type="pmcid">PMC7334617</pub-id><pub-id pub-id-type="pmid">32629423</pub-id></mixed-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Integrative analysis of the molecular mechanisms, immunological features and immunotherapy response of ferroptosis regulators across 33 cancer types</article-title><source>Int J Biol Sci</source><volume>18</volume><year>2022</year><fpage>180</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">34975326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.64654</pub-id><pub-id pub-id-type="pmcid">PMC8692154</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Genomic analysis uncovers prognostic and immunogenic characteristics of ferroptosis for clear cell renal cell carcinoma</article-title><source>Mol Ther Nucleic Acids</source><volume>25</volume><year>2021</year><fpage>186</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">34458004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2021.05.009</pub-id><pub-id pub-id-type="pmcid">PMC8368772</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name name-style="western"><surname>Mhaidly</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mechta-Grigoriou</surname><given-names>F.</given-names></name></person-group><article-title>Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer</article-title><source>Immunol Rev</source><volume>302</volume><year>2021</year><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">34013544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12978</pub-id><pub-id pub-id-type="pmcid">PMC8360036</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name name-style="western"><surname>Charoentong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Finotello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Angelova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Efremova</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade</article-title><source>Cell Rep</source><volume>18</volume><year>2017</year><fpage>248</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">28052254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.12.019</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>B.</given-names></name></person-group><article-title>Targeting ferroptosis as a vulnerability in cancer</article-title><source>Nat Rev Cancer</source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-022-00459-0</pub-id><pub-id pub-id-type="pmcid">PMC10243716</pub-id><pub-id pub-id-type="pmid">35338310</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name></person-group><article-title>Broadening horizons: the role of ferroptosis in cancer</article-title><source>Nat Rev Clin Oncol</source><volume>18</volume><year>2021</year><fpage>280</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">33514910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-020-00462-0</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Overexpression of TPX2 predicts poor clinical outcome and is associated with immune infiltration in hepatic cell cancer</article-title><source>Medicine (Baltimore)</source><volume>99</volume><year>2020</year><fpage>e23554</fpage><pub-id pub-id-type="pmid">33285774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000023554</pub-id><pub-id pub-id-type="pmcid">PMC7717782</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Prognostic biomarker TUBA1C is correlated to immune cell infiltration in the tumor microenvironment of lung adenocarcinoma</article-title><source>Cancer Cell Int</source><volume>21</volume><year>2021</year><fpage>144</fpage><pub-id pub-id-type="pmid">33653340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-021-01849-4</pub-id><pub-id pub-id-type="pmcid">PMC7923461</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group><article-title>TUBA1C is a prognostic marker in low-grade glioma and correlates with immune cell infiltration in the tumor microenvironment</article-title><source>Front Genet</source><volume>12</volume><year>2021</year><fpage>759953</fpage><pub-id pub-id-type="pmid">34721547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2021.759953</pub-id><pub-id pub-id-type="pmcid">PMC8553001</pub-id></element-citation></ref><ref id="b0335"><label>67</label><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name name-style="western"><surname>Cejalvo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gargini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Segura-Collar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mata-Martinez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Herranz</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Immune profiling of gliomas reveals a connection with IDH1/2 mutations, tau function and the vascular phenotype</article-title><source>Cancers (Basel)</source><volume>12</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12113230</pub-id><pub-id pub-id-type="pmcid">PMC7694073</pub-id><pub-id pub-id-type="pmid">33147752</pub-id></element-citation></ref><ref id="b0340"><label>68</label><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Prognostic biomarker MITD1 and its correlation with immune infiltrates in hepatocellular carcinoma (HCC)</article-title><source>Int Immunopharmacol</source><volume>81</volume><year>2020</year><fpage>106222</fpage><pub-id pub-id-type="pmid">32007795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106222</pub-id></element-citation></ref><ref id="b0345"><label>69</label><mixed-citation publication-type="other" id="h0345">Chen C, Sheng Y. Prognostic impact of MITD1 and associates with immune infiltration in kidney renal clear cell carcinoma. Technol Cancer Res Treat 2021; 20:15330338211036233.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/15330338211036233</pub-id><pub-id pub-id-type="pmcid">PMC8351032</pub-id><pub-id pub-id-type="pmid">34346239</pub-id></mixed-citation></ref><ref id="b0350"><label>70</label><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Integrative analysis of prognostic value and immune infiltration of spindle and kinetochore-associated family members in breast cancer</article-title><source>Bioengineered</source><volume>12</volume><year>2021</year><fpage>10905</fpage><lpage>10923</lpage><pub-id pub-id-type="pmid">34845974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21655979.2021.1995576</pub-id><pub-id pub-id-type="pmcid">PMC8809973</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.Q.</given-names></name><etal/></person-group><article-title>Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma</article-title><source>Sci Rep</source><volume>11</volume><year>2021</year><fpage>11165</fpage><pub-id pub-id-type="pmid">34045512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-89628-z</pub-id><pub-id pub-id-type="pmcid">PMC8160131</pub-id></element-citation></ref></ref-list><sec id="s0130" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0285">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0010" position="float" orientation="portrait"><caption><title>Supplementary data 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material></p><p id="p0290">
<supplementary-material content-type="local-data" id="m0005" position="float" orientation="portrait"><caption><title>Supplementary data 2</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.xlsx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ak005"><title>Acknowledgements</title><p id="p0275">We thank the members of our research center for inspiring discussion.</p></ack><fn-group><fn id="s0125" fn-type="supplementary-material"><label>Appendix A</label><p id="p0280">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.csbj.2022.06.046" id="ir120">https://doi.org/10.1016/j.csbj.2022.06.046</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>